Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01295710 · ClinicalTrials.gov registry record · Phase 3
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
A Phase 3 study of Myelodysplastic Syndrome and GvHD, sponsored by Neovii Biotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
- 20
- Study locations
NCT01295710 is a Phase 3 study of Myelodysplastic Syndrome and GvHD that has completed, run by Neovii Biotech. The registered enrollment target is 260 participants, above the 205-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01295710, a Phase 3 study of Myelodysplastic Syndrome and GvHD, has completed, sponsored by Neovii Biotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL US-ATG-F
Study Locations (20)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
California
- City of Hope - Duarte
- Stanford University Medical Center, BMT - Stanford
Florida
- University of Florida Shands Cancer Center - Gainesville
- Moffitt Cancer Center - Tampa
Illinois
- University of Chicago Medical Center - Chicago
- Loyola University Medical Center - Maywood
North Carolina
- University of North Carolina Hospitals - Chapel Hill
- Duke University Medical Center - Durham
Pennsylvania
- Penn State Hershey Cancer Institute - Hershey
- Abramson Cancer Center of the University at Perlman Center for Advanced Medicine - Philadelphia
Kansas
- University of Kansas Medical Center - Westwood
Louisiana
- Tulane University Health Sciences Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2011-10-10 |
| Est. Completion | 2015-10-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01295710
The ClinicalTrials.gov registry entry for NCT01295710 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (27% higher). The listed sponsor is Neovii Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01295710 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Massachusetts, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01295710 about?
NCT01295710 is a clinical study titled "Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)". The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.
What is the current status of trial NCT01295710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2011-10-10. Estimated completion is 2015-10-15.
What conditions does trial NCT01295710 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, GvHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia.
What interventions are being tested in trial NCT01295710?
The interventions under investigation include: Placebo (BIOLOGICAL), US-ATG-F (BIOLOGICAL).
Who is sponsoring clinical trial NCT01295710?
This trial is sponsored by Neovii Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01295710 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.